サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ペプチド薬物複合体の世界市場：2023年～2030年
市場調査レポート
商品コード
1380413

ペプチド薬物複合体の世界市場：2023年～2030年

Global Peptide Drug Conjugates Market 2023-2030

出版日
ページ情報
英文 200 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
ペプチド薬物複合体の世界市場：2023年～2030年
出版日: 2023年09月27日
発行: Orion Market Research
ページ情報: 英文 200 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ペプチド薬物複合体の世界市場は予測期間（2023年～2030年）にCAGR 9.4％で成長すると予測されます。この市場の背景には、がんや代謝性疾患の有病率の増加、新薬の研究開発投資の増加、医薬品開発の技術進歩などがあります。Globocan 2020によると、がん患者数は5,055万287人です。そのうち1,929万2,789人が新たにがんと診断されました。

セグメント別展望

ペプチド薬物複合体の世界市場では、メルフルフェンのサブセグメントが大きなシェアを占めると予想されます。

製品の中でも、メルフルフェンのサブセグメントが世界のペプチド薬物複合体市場でかなりのシェアを占めると予想されています。このセグメントの成長は、現在の治療オプションに関する認知度の向上、有利な償還政策、メルフルフェンの発売、がん治療におけるPDC薬剤の急速な普及に起因しています。2021年2月、FDAは、デキサメタゾンとの併用で使用する最初の抗がんペプチド薬物複合体、メルファランフルフェナミド（メルフルフェン）を承認しました。第2相HORIZON調査に基づき、スウェーデンのバイオテクノロジー企業Oncopeptides ABが開発したこの製品は、早期承認を受けた。本剤は、4種類以上の前治療歴があり、少なくとも1種類のプロテアソーム阻害剤、1種類の免疫調節剤、および1種類のCD38指向性モノクローナル抗体に抵抗性を示す難治性多発性骨髄腫の成人患者を対象としています。

地域別展望

ペプチド薬物複合体の世界市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。なかでもアジア太平洋地域は、新しい送達システムを開発・商業化するための投資が増加していることから、世界全体で突出したシェアを占めると予想されます。

北米地域はペプチド薬物複合体の世界市場で大きなCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予想されています。北米市場を牽引する主な要因は、同地域全体でがん患者が増加していることであり、今後数年間はペプチド薬物複合体市場の成長に確実に影響を与えると推定されます。米国がん協会（ACS）によると、2022年には米国で約191万8,030人の新規がん患者と60万9,360人のがん死亡者が報告されました。Royal Society Publishing Organizationの報告によると、ハイブリッドペプチドであるHPRP-A1-TATは、細胞膜を破壊して細胞質の内容物を急速に漏出させることができ、強い抗がん作用を持つ。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Angiochem Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Bicycle Therapeutics, Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Cybrexa Therapeutics Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Novartis AG
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Oncopeptides AB
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • ペプチド薬物複合体の世界市場：タイプ別
    • 診断薬
    • 治療薬
  • ペプチド薬物複合体の世界市場：製品別
    • メルフルフェン
    • ルテチウム
    • ANG1005
    • BT1718
    • CBX-12

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • AstraZeneca co.
  • Camurus AB
  • Chiasma, Inc.
  • CRINETICS PHARMACEUTICALS
  • Dauntless Pharmaceuticals
  • Ipsen Biopharmaceuticals, Inc.
  • Midatech Pharma PLC
  • PeptiDream Inc.
  • Peptron, Inc.
  • Pfizer Inc.,
  • Soricimed Biopharma
  • Teva Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Validus Pharmaceuticals LLC
  • WuXi AppTec Co., Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 12. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 13. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 14. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 15. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 16. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 17. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 18. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 19. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 20. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
  • 21. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. US PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 12. CANADA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 13. UK PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 14. FRANCE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 15. GERMANY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 16. ITALY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 17. SPAIN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 18. REST OF EUROPE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. INDIA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. CHINA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. JAPAN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. SOUTH KOREA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. REST OF ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027822

Title: Global Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Type (Diagnostic and Therapeutic), and by Product (Melflufen, Lutetium, ANG1005, BT1718 and CBX-12),Forecast Period (2023-2030).

The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the Forecast Period (2023-2030). The market is attributed to factors including the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development. According to the Globocan 2020, number of cancer cases were 50,550,287. Of which, the total number of new cases 19,292,789 around the globe.

Segmental Outlook

The global peptide drug conjugates market is segmented on the type, and product. Based on the type, the market is sub-segmented into diagnostic and therapeutic. Based on the product, the market is sub-segmented into melflufen, lutetium, ANG1005, BT1718 and CBX-12. Among the type, the therapeutic sub-segment is anticipated to hold a considerable share of the market, owing to the emerging targeted therapeutic that present increased tumor penetration and selectivity.

The Melflufen Sub-Segment is Anticipated to Hold a Considerable Share of the Global Peptide Drug Conjugates Market

Among the product, the melflufen sub-segment is expected to hold a considerable share of the global Peptide Drug Conjugates market. The segmental growth is attributed to the owing to increasing awareness about current treatment options, favorable reimbursement policies, the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy., In February 2021, the FDA approved the first anticancer peptide-drug conjugate, melphalan flufenamide, or melflufen, for use in combination with dexamethasone. Based on the phase 2 HORIZON research, the product, developed by the Swedish biotech company Oncopeptides AB, received accelerated approval. In adult patients with refractory multiple myeloma, who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Regional Outlook

The global peptide drug conjugates market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the rising investments to develop and commercialize new delivery systems.

The North America Region is Expected to Grow at a Significant CAGR in the Global Peptide Drug Conjugates Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market is the increasing number of cancer cases across the region is estimated to certainly impact the peptide drug conjugates market growth in upcoming years. According to the American Cancer Society (ACS), in 2022, around 1,918,030 new cancer cases and 609,360 cancer mortalities were reported in the US. As per the reports of Royal Society Publishing Organization, HPRP-A1-TAT, a hybrid peptide, can destroy the cell membrane to cause rapid leakage of cytoplasmic contents, and has a strong anti-cancer activity.

Market Players Outlook

The major companies serving the global peptide drug conjugates market include: Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Novartis AG, Oncopeptides AB, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company entered into a new multi-target collaboration and license agreement with US based Genentech, a member of the Roche Group, targeted on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global peptide drug conjugates market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Angiochem Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bicycle Therapeutics, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Cybrexa Therapeutics Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Novartis AG
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Oncopeptides AB
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Peptide Drug Conjugates Market by Type
    • 4.1.1. Diagnostic
    • 4.1.2. Therapeutic
  • 4.2. Global Peptide Drug Conjugates Market by Product
    • 4.2.1. Melflufen
    • 4.2.2. Lutetium
    • 4.2.3. ANG1005
    • 4.2.4. BT1718
    • 4.2.5. CBX-12

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. AstraZeneca co.
  • 6.2. Camurus AB
  • 6.3. Chiasma, Inc.
  • 6.4. CRINETICS PHARMACEUTICALS
  • 6.5. Dauntless Pharmaceuticals
  • 6.6. Ipsen Biopharmaceuticals, Inc.
  • 6.7. Midatech Pharma PLC
  • 6.8. PeptiDream Inc.
  • 6.9. Peptron, Inc.
  • 6.10. Pfizer Inc.,
  • 6.11. Soricimed Biopharma
  • 6.12. Teva Pharmaceuticals Inc.
  • 6.13. Theratechnologies Inc.
  • 6.14. Validus Pharmaceuticals LLC
  • 6.15. WuXi AppTec Co., Ltd.